Northern Arizona Pulmonary Associates
Pulmonology
Dr. Douglas W. Mapel, MD
|
|
Give Review
Douglas Mapel is an expert in the field of Pulmonology. He received awards:"Fellow (FACP)" and "Whos Who in Medicine and Healthcare". Douglas W. Mapel, MD is a published doctor as well. He has 60 publications published. The latest was: Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Economic evaluations of fluticasone-propionate/salmeterol combination therapy for Chronic obstructive pulmonary disease: a review of published studies.
- Management of Asthma and Chronic Obstructive Pulmonary Disease with Combination Inhaled Corticosteroids and Long-Acting β-Agonists: A Review of Comparative Effectivene...
- Renal and hepatobiliary dysfunction in Chronic obstructive pulmonary disease.
- Functional disorders of the gastrointestinal tract: Cost effectiveness review.
- Chronic pain and pain medication use in Chronic obstructive pulmonary disease. A cross-sectional study.
- Prevalence of renal and hepatobiliary disease, laboratory abnormalities, and potentially toxic medication exposures among persons with COPD.
- The epidemiology, diagnosis, and cost of dyspepsia and Helicobacter pylori gastritis: a case-control analysis in the Southwestern United States.
- Prevalence of airway obstruction assessed by Lung function questionnaire.
- COPD-related healthcare utilization and costs after discharge from a hospitalization or emergency department visit on a regimen of fluticasone propionate-salmeterol co...
- Impact of maintenance therapy on hospitalization and expenditures for Medicare beneficiaries with Chronic obstructive pulmonary disease.
- Can outpatient pharmacy data identify persons with undiagnosed COPD?
- A comparison of health-care costs in patients with Chronic obstructive pulmonary disease using lightweight portable oxygen systems versus traditional compressed-oxygen...
- Predictive validity of short-form health survey [36 items] scales for Chronic obstructive pulmonary disease exacerbation.
- COPD as a Lung disease with systemic consequences--clinical impact, mechanisms, and potential for early intervention.
- The direct medical costs of undiagnosed Chronic obstructive pulmonary disease.
- Burden of concomitant Asthma and COPD in a Medicaid population.
- Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone.
- Estimating the cost of COPD--a matter of perspective.
- An algorithm for the identification of undiagnosed COPD cases using administrative claims data.
- Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991-1999.
- Treatment implications on morbidity and mortality in COPD.
- Undiagnosed airflow obstruction: prevalence and implications.
- A 47-year-old woman with wheezing and Respiratory failure unresponsive to conventional ventilatory modalities.
- Obtaining evidence for use by healthcare payers on the success of Chronic obstructive pulmonary disease management.
- The health impact of undiagnosed airflow obstruction in a national sample of United States adults.
- Esophageal rupture after regional anesthesia: report of two cases.
- Primary mediastinal malignancies: findings in 219 patients.
- Idiopathic Pulmonary fibrosis: survival in population based and hospital based cohorts.
- Mediastinitis without antecedent surgery.
- Ethnic differences in the prevalence of nonmalignant respiratory Disease among uranium miners.
- Adenocarcinoma of the Lung presenting as a diffuse interstitial process in a 25-year-old man.
- Corticosteroids and the treatment of idiopathic Pulmonary fibrosis. Past, present, and future.
- Radiologic case. Right hilar mass. Squamous cell carcinoma of the esophagus with hilar metastasis.
- Health care utilization in Chronic obstructive pulmonary disease. A case-control study in a health maintenance organization.
- Hemoptysis season.
- Utilization in COPD: patient characteristics and diagnostic evaluation.
- The cost of Chronic obstructive pulmonary disease and its effects on managed care.
- Hospital, pharmacy, and outpatient costs for osteoarthritis and Chronic back pain.
- The pharmacoepidemiology of COPD: recent advances and methodological discussion.
- Improved survival in COPD: reasons for hope.
- Development of the Lung Function Questionnaire (LFQ) to identify airflow obstruction.
- The role of combination inhaled corticosteroid/long-acting beta-agonist therapy in COPD management.
- Predicting risk of airflow obstruction in primary care: Validation of the Lung function questionnaire (LFQ).
- Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators.
- Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
- Recommendations of the 6th long-term oxygen therapy consensus conference.
- The natural history of Chronic obstructive pulmonary disease.
- Economic evaluation of treating Chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization.
- Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists.
- Predicting the costs of managing patients with Chronic obstructive pulmonary disease.
- Economic burden of chronic Bronchitis in the United States: a retrospective case-control study.
- Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for Chronic obstructive pulmon...
- Adherence to controller therapy for Chronic obstructive pulmonary disease: a review.
- A new method for examining the cost savings of reducing COPD exacerbations.
- Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data.
- Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients.
- Insights into COPD comorbidities from the OLIN study and other large databases.
- Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims.
- Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.
Schools
University Of Texas Medical Branch At Galveston
Texas Tech University of Health Sciences Center
University Of New Mexico School Of Medicine
Procedures Preformed
- Bronchoscopy
- Thoracentesis
- Ventilation Management
Conditions Treated
- Acidosis
- Alkalosis
- Asbestosis
- Asthma
- View All
Doctors Specialties
- Critical Care Medicine
- Pulmonology
Accepted Insurances
Awards
- Fellow (FACP)
- Whos Who in Medicine and Healthcare
Education
-
University of New Mexico -
Texas Tech University at Lubbock -
University of Texas Medical Branch
Drug Facts
| NPI NUMBER | 1497730451 | |
| NPPES Provider LastName | MAPEL | |
| NPPES Provider FirstName | DOUGLAS | |
| NPPES Provider ZIPCode | 86001 | |
| NPPES Provider State | AZ | |
| Specialty Description | Critical Care (Intensivists) | |
| Total Claim Count | 290.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1497730451 |
| Last Name Of The Provider | MAPEL |
| First Name Of The Provider | DOUGLAS |
| View All |
Similar Doctors
|
|
Dr. Henry W. Luedy, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Theodore H. Lewis Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brent M. Cutshall, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert S. Rosenberg, DO |
|
|
Dr. Mastian G. Chand, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James D. McDaniel, MD |